Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application ...

Those who have used psilocybin or LSD may be familiar with the experience: The day following your trip, it’s back to reality, yet there are still glimmers of your previous day’s journey, a fleeting ...

A recent study published in the journal Scientific Reports found evidence that MDMA can be a beneficial treatment for specific mental health-related conditions. The study consisted of eight ...

Lysergic acid diethylamide (LSD), psilocybin (the psychoactive compound in “magic mushrooms”) and mescaline are three of the most widely studied classic psychedelics. Each has a long history of ...

When Snehal Bhatt left New Jersey for New Mexico in 2009, he was reluctant to tell people about his research goals. Now a faculty member at Rutgers' Robert Wood Johnson Medical School and a professor ...

A mid-stage study of a pharmaceutical version of the psychedelic LSD reported the drug might help alleviate anxiety symptoms for up to three months, advancing a potential treatment for the most common ...

Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances with that of classic drugs. It further eliminates the criteria ...

In a review of previous studies, McMaster University researchers observe a stronger signal for psilocybin as a treatment for ...

Recent analysis of federal health data suggests that the recreational use of LSD is associated with a lower likelihood of ...

New studies show that psychedelics could unlock safer treatments for chronic pain, mood disorders, and even neuroprotection.

Emerging evidence highlights psilocybin as a potential therapy for treatment-resistant OCD, while cannabinoids show limited ...